Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Takeda divests non-core assets to Acino in deal worth over $200mm

Executive Summary

Takeda Pharmaceutical Co. Ltd. will divest 30 select over-the-counter and prescription to products to Swiss company Acino, which will pay over $200mm to gain exclusive rights to the products in Near East, Middle East, and Africa nations specifically including Egypt, Saudi Arabia, South Africa, Turkey, Ukraine, and the United Arab Emirates, among others.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Product Purchase

Related Companies